PRISMA: Telmisartan vs Ramipril in Hypertension

Phase 4, randomised, open-label trial of telmisartan in hypertension (HTN) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Mean Ambulatory Diastolic Blood Pressure during the last 6 hours of the dosing interval at 14 weeks and Mean Ambulatory Systolic Blood Pressure during the last 6 hours of the dosing interval at 14 weeks. Started Oct 2002; status: completed.